ArticleExperimental biology and medicine (Maywood, N.J.)2015
Aplysin induces apoptosis in glioma cells through HSP90/AKT pathway.
Article in Experimental biology and medicine (Maywood, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Trial
- Ginkgetin inhibits non-small cell lung cancer via the HSP90-AKT signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Bioactive Compounds with Antiglioma Activity from Marine Species.Biomedicines · 2021Review
- MAPK signaling pathway-targeted marine compounds in cancer therapy.Journal of cancer research and clinical oncology · 2021Review
- Bioactive Compounds from Marine Heterobranchs.Marine drugs · 2020Review
- Bioactive compounds from marine invertebrates as potent anticancer drugs: the possible pharmacophores modulating cell death pathways.Molecular biology reports · 2020Review
- Antimycobacterial Activity of Laurinterol and Aplysin fromMarine drugs · 2020Article
- Antitumoral Effect of Laurinterol on 3D Culture of Breast Cancer Explants.Marine drugs · 2019Article
- Modelling cadmium-induced cardiotoxicity using human pluripotent stem cell-derived cardiomyocytes.Journal of cellular and molecular medicine · 2018Article
- Trifluoperazine induces apoptosis through the upregulation of Bax/Bcl‑2 and downregulated phosphorylation of AKT in mesangial cells and improves renal function in lupus nephritis mice.International journal of molecular medicine · 2018Article
- Breast cancer suppression by aplysin is associated with inhibition of PI3K/AKT/FOXO3a pathway.Oncotarget · 2017Article
- Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.Medicinal research reviews · 2017Review
- Protective effect of aplysin on liver tissue and the gut microbiota in alcohol-fed rats.PloS one · 2017Article
- Chemical Diversity and Biological Properties of Secondary Metabolites from Sea Hares of Aplysia Genus.Marine drugs · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is one of the most common malignancies in the world. However, an effective regiment is lacking. Increasing evidence indicated that PI3K/AKT signaling is critical for the survival of glioma. In this study, we aimed to study the effect of aplysin on the survival and proliferation of GL26 glioma cells and the involved mechanisms. The data showed that aplysin suppressed the viability of glioma cells in both dose- and time-dependent manners. It also induced G0/G1 arrest and apoptosis in glioma cells. Western blot assays revealed that aplysin treatment changed p-AKT expression by impairing the formation of Heat shock protein 90/AKT complex. Aplysin significantly increased the survival time of mice-bearing glioma and reduced the weights of the established gliomas. Collectively, aplysin can inhibit the proliferation of GL26 glioma cells and induce apoptosis in vitro, perhaps through suppressing PI3K/AKT pathway. It can also inhibit glioma growth in vivo and prolong the survival of mice. Thus, aplysin may be a novel therapeutic drug for glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.